Pfizer Ventures participated in a series A round for genetic therapeutics developer Anjarium Biosciences that was co-led by Abingworth and Gimv.
Switzerland-based gene therapy developer Anjarium Biosciences has completed a CHF55.5m ($60m) series A round that included Pfizer Ventures, the strategic investment arm of pharmaceutical firm Pfizer.
Investment firms Abingworth and Gimv co-led the round, which also featured private equity firm Omega Funds and Surveyor Capital, a subsidiary of hedge fund manager Citadel.
Anjarium is developing non-viral tissue-targeted gene therapies to treat genetic diseases. It intends to channel the funding into platform development, increasing its staff numbers and advancing its product…
